Northwest Biotherapeutics (STU:NBYB) Cyclically Adjusted PB Ratio: (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NBYB Northwest Biotherapeutics Inc STU:NBYB
17 GF Score
Price €0.18
GF Value €0.24
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Northwest Biotherapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Northwest Biotherapeutics  (STU:NBYB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Northwest Biotherapeutics Cyclically Adjusted PB Ratio Related Terms


Northwest Biotherapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Northwest Biotherapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Biotherapeutics Cyclically Adjusted PB Ratio Chart

Northwest Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Northwest Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:NBYB vs FATE, IMRX, FHTX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Northwest Biotherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Northwest Biotherapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Cyclically Adjusted PB Ratio falls into.


STU:NBYB
17GF Score
Northwest Biotherapeutics Inc STU:NBYB
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Northwest Biotherapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Northwest Biotherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Northwest Biotherapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.027/330.2130*330.2130
=-0.027

Current CPI (Mar. 2026) = 330.2130.

Northwest Biotherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 -0.159 241.018 -0.218
201609 -0.037 241.428 -0.051
201612 -0.160 241.432 -0.219
201703 -0.185 243.801 -0.251
201706 -0.132 244.955 -0.178
201709 -0.116 246.819 -0.155
201712 -0.173 246.524 -0.232
201803 -0.158 249.554 -0.209
201806 -0.162 251.989 -0.212
201809 -0.079 252.439 -0.103
201812 -0.079 251.233 -0.104
201903 -0.096 254.202 -0.125
201906 -0.083 256.143 -0.107
201909 -0.085 256.759 -0.109
201912 -0.066 256.974 -0.085
202003 -0.048 258.115 -0.061
202006 -0.100 257.797 -0.128
202009 -0.231 260.280 -0.293
202012 -0.360 260.474 -0.456
202103 -0.352 264.877 -0.439
202106 -0.339 271.696 -0.412
202109 -0.288 274.310 -0.347
202112 -0.116 278.802 -0.137
202203 -0.113 287.504 -0.130
202206 -0.084 296.311 -0.094
202209 -0.105 296.808 -0.117
202212 -0.113 296.797 -0.126
202303 -0.048 301.836 -0.053
202306 -0.051 305.109 -0.055
202309 -0.053 307.789 -0.057
202312 -0.051 306.746 -0.055
202403 -0.056 312.332 -0.059
202406 -0.058 314.175 -0.061
202409 -0.056 315.301 -0.059
202412 -0.068 315.605 -0.071
202503 -0.066 319.799 -0.068
202506 -0.060 322.561 -0.061
202509 -0.061 324.800 -0.062
202512 -0.033 324.054 -0.034
202603 -0.027 330.213 -0.027

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Northwest Biotherapeutics (STU:NBYB) Overvalued in 2026?

Based on GuruFocus' analysis, Northwest Biotherapeutics stock appears to be undervalued. The current stock price of €0.18 is trading 25% below its estimated GF Value™ of €0.24. GuruFocus considers Northwest Biotherapeutics to be Modestly Undervalued.

Key valuation signals for STU:NBYB:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €0.24 vs. price of €0.18 (25% below fair value)
  • GF Score™: 17/100 with 5 warning signs

No single metric tells the full story. See the STU:NBYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Northwest Biotherapeutics Business Description

Other Exchanges NWBO:USA
Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
17GF Score

Get the complete analysis for STU:NBYB

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.18
Price
€0.24
GF Value